Abstract
Study of ocular pharmacology, pharmacodynamics, and toxicology is challenging due to the inherent ocular barriers to drug penetration, small ocular tissue sizes and volumes, and sensitive ocular structures. Additionally, wide variation of ocular sizes and physiology among animal models complicates simple translation of results from one species of animal to another. This chapter, and those to follow, will describe the challenges researchers face regarding ocular pharmacology and toxicology as well as providing them with practical methodologies for conducting studies, including study design and specialized methodology, to overcome these challenges and thus improve treatment of ocular disease.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Weiner AL, Gilger BC (2010) Advancements in ocular drug delivery. Vet Ophthalmol 13(6):395–406
Kim SH, Lutz RJ, Wang NS, Robinson MR (2007) Transport barriers in transscleral drug delivery for retinal diseases. Ophthalmic Res 39(5):244–254
Kim SH, Galban CJ, Lutz RJ, Dedrick RL, Csaky KG, Lizak MJ, Wang NS, Tansey G, Robinson MR (2007) Assessment of subconjunctival and intrascleral drug delivery to the posterior segment using dynamic contrast-enhanced magnetic resonance imaging. Invest Ophthalmol Vis Sci 48(2):808–814
Robinson MR, Lee SS, Kim H, Kim S, Lutz RJ, Galban C, Bungay PM, Yuan P, Wang NS, Kim J, Csaky KG (2006) A rabbit model for assessing the ocular barriers to the transscleral delivery of triamcinolone acetonide. Exp Eye Res 82(3):479–487
Kim H, Lizak MJ, Tansey G, Csaky KG, Robinson MR, Yuan P, Wang NS, Lutz RJ (2005) Study of ocular transport of drugs released from an intravitreal implant using magnetic resonance imaging. Ann Biomed Eng 33(2):150–164
Kim H, Robinson MR, Lizak MJ, Tansey G, Lutz RJ, Yuan P, Wang NS, Csaky KG (2004) Controlled drug release from an ocular implant: an evaluation using dynamic three-dimensional magnetic resonance imaging. Invest Ophthalmol Vis Sci 45(8):2722–2731
Davis JL, Gilger BC, Robinson MR (2004) Novel approaches to ocular drug delivery. Curr Opin Mol Ther 6(2):195–205
Lee TW, Robinson JR (2001) Drug delivery to the posterior segment of the eye: some insights on the penetration pathways after subconjunctival injection. J Ocul Pharmacol Ther 17(6):565–572
Cruysberg LP, Nuijts RM, Gilbert JA, Geroski DH, Hendrikse F, Edelhauser HF (2005) In vitro sustained human transscleral drug delivery of fluorescein-labeled dexamethasone and methotrexate with fibrin sealant. Curr Eye Res 30(8):653–660
Lee SB, Geroski DH, Prausnitz MR, Edelhauser HF (2004) Drug delivery through the sclera: effects of thickness, hydration, and sustained release systems. Exp Eye Res 78(3):599–607
Patel SR, Lin AS, Edelhauser HF, Prausnitz MR (2011) Suprachoroidal drug delivery to the back of the eye using hollow microneedles. Pharm Res 28(1):166–176
Robinson MR, Whitcup SM (2012) Pharmacologic and clinical profile of dexamethasone intravitreal implant. Exp Rev Clin Pharmacol 5(6):629–647
Simpson AE, Gilbert JA, Rudnick DE, Geroski DH, Aaberg TM Jr, Edelhauser HF (2002) Transscleral diffusion of carboplatin: an in vitro and in vivo study. Arch Ophthalmol 120(8):1069–1074
Lee SS, Kim H, Wang NS, Bungay PM, Gilger BC, Yuan P, Kim J, Csaky KG, Robinson MR (2007) A pharmacokinetic and safety evaluation of an episcleral cyclosporine implant for potential use in high-risk keratoplasty rejection. Invest Ophthalmol Vis Sci 48(5):2023–2029
Gilger BC, Salmon JH, Wilkie DA, Cruysberg LP, Kim J, Hayat M, Kim H, Kim S, Yuan P, Lee SS, Harrington SM, Murray PR, Edelhauser HF, Csaky KG, Robinson MR (2006) A novel bioerodible deep scleral lamellar cyclosporine implant for uveitis. Invest Ophthalmol Vis Sci 47(6):2596–2605
Gilger BC, Wilkie DA, Clode AB, McMullen RJ Jr, Utter ME, Komaromy AM, Brooks DE, Salmon JH (2010) Long-term outcome after implantation of a suprachoroidal cyclosporine drug delivery device in horses with recurrent uveitis. Vet Ophthalmol 13(5):294–300
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2013 Springer Science+Business Media New York
About this protocol
Cite this protocol
Gilger, B.C. (2013). Challenges in Ocular Pharmacokinetics, Pharmacodynamics, and Toxicology. In: Gilger, B. (eds) Ocular Pharmacology and Toxicology. Methods in Pharmacology and Toxicology. Humana Press, Totowa, NJ. https://doi.org/10.1007/7653_2013_1
Download citation
DOI: https://doi.org/10.1007/7653_2013_1
Published:
Publisher Name: Humana Press, Totowa, NJ
Print ISBN: 978-1-62703-744-0
Online ISBN: 978-1-62703-745-7
eBook Packages: Springer Protocols